TMO
Thermo Fisher Scientific Inc.
Price Chart
Latest Quote
$472.80
-9.23 (-1.91%)
Current Price
| Previous Close | $482.03 |
| Open | $484.22 |
| Day High | $486.56 |
| Day Low | $469.62 |
| Volume | 1,244,342 |
Stock Information
| Quarterly Dividend / Yield | $1.88 / 0.39% |
| Shares Outstanding | 371.62M |
| Quarterly Dividend Yield | 0.39% |
| Quarterly Dividend | $1.88 |
| Total Debt | $43.16B |
| Cash Equivalents | $3.26B |
| Revenue | $45.20B |
| Net Income | $6.85B |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $175.70B |
| P/E Ratio | 26.02 |
| EPS (TTM) | $18.17 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $219.17B |
| Sales | $45.20B |
| Income | $6.85B |
| Book/sh | $141.96 |
| Cash/sh | $8.76 |
| Employees | 125K |
Financial Ratios
| Quick Ratio | 0.97 |
| Current Ratio | 1.53 |
| Debt/Eq | 82.90 |
| EPS Growth TTM | 9.60% |
Returns & Margins
| ROA | 5.00% |
| ROE | 13.52% |
| Gross Margin | 40.93% |
| Operating Margin | 17.89% |
| Profit Margin | 15.15% |
Ownership
| Insider Ownership | 0.15% |
| Institutional Ownership | 94.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 17.34 |
| PEG | 1.59 |
| P/S | 3.89 |
| P/B | 3.33 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $602.76 |
Technical Indicators
| SMA20 | $461.89 |
| SMA50 | $479.63 |
| SMA200 | $526.00 |
| RSI | 67.18 |
| ATR | 14.4825 |
| Shares Float | 370.67M |
| Short Float | 1.29% |
| Short Ratio | 2.00 |
| Volatility | 0.87 |
| Rel Volume | 0.46 |
Performance History
| Week | -4.00% |
| Month | -0.03% |
| Quarter | -5.72% |
| 6 Months | -18.40% |
| YTD | -20.12% |
| Year | +17.56% |
| 3 Years | -6.15% |
| 5 Years | +2.08% |
| 10 Years | +217.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $472.80 | 1,244,342 |
| 2026-06-04 | $482.03 | 2,241,900 |
| 2026-06-03 | $473.95 | 1,938,900 |
| 2026-06-02 | $482.08 | 1,774,500 |
| 2026-06-01 | $494.04 | 3,194,400 |
| 2026-05-29 | $492.51 | 4,184,100 |
| 2026-05-28 | $487.22 | 4,372,700 |
| 2026-05-27 | $456.21 | 2,958,600 |
| 2026-05-26 | $448.18 | 1,942,600 |
| 2026-05-22 | $448.28 | 1,686,100 |
| 2026-05-21 | $449.37 | 2,012,700 |
| 2026-05-20 | $451.79 | 2,851,600 |
| 2026-05-19 | $447.81 | 3,418,500 |
| 2026-05-18 | $442.00 | 1,908,500 |
| 2026-05-15 | $438.34 | 2,037,800 |
| 2026-05-14 | $448.21 | 2,100,300 |
| 2026-05-13 | $446.03 | 2,801,200 |
| 2026-05-12 | $459.30 | 3,055,700 |
| 2026-05-11 | $452.60 | 3,952,900 |
| 2026-05-08 | $465.00 | 3,905,600 |
| 2026-05-07 | $474.46 | 2,533,600 |
| 2026-05-06 | $472.95 | 1,861,500 |
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
đ° Latest News
ICLR Earnings Reset: What the Accounting Probe Changed
Zacks âĸ 2026-06-05T18:09:00Z
The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches â Learn Why
Simply Wall St. âĸ 2026-06-05T00:17:24Z
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-04T15:30:29Z
Jim Cramer on Danaher: âAt These Prices, Itâs Clearly Overvaluedâ
Insider Monkey âĸ 2026-06-04T10:58:30Z
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
Zacks âĸ 2026-06-03T17:44:00Z
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-03T13:55:44Z
Is Thermo Fisher Scientific (TMO) Pricing Look Interesting After Recent Share Price Swings
Simply Wall St. âĸ 2026-06-02T11:16:17Z
The Zacks Analyst Blog Highlights Microsoft, Dell, Thermo Fisher,Village Super Market and Comstock
Zacks âĸ 2026-06-02T08:08:00Z
Top Analyst Reports for Microsoft, Dell & Thermo Fisher
Zacks âĸ 2026-06-01T20:40:00Z2 of Wall Streetâs Favorite Stocks with Exciting Potential and 1 Facing Challenges
StockStory âĸ 2026-06-01T17:36:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $26,318,000,000 | $25,177,000,000 | $25,757,000,000 | $25,944,000,000 |
| Cost Of Revenue | $26,318,000,000 | $25,177,000,000 | $25,757,000,000 | $25,944,000,000 |
| Total Revenue | $44,557,000,000 | $42,879,000,000 | $42,857,000,000 | $44,915,000,000 |
| Operating Revenue | $44,557,000,000 | $42,879,000,000 | $42,857,000,000 | $44,915,000,000 |
| Expenses | ||||
| Interest Expense | $1,419,000,000 | $1,390,000,000 | $1,375,000,000 | $726,000,000 |
| Total Expenses | $36,447,000,000 | $35,162,000,000 | $35,539,000,000 | $36,408,000,000 |
| Other Income Expense | $-374,000,000 | $-367,000,000 | $-524,000,000 | $-218,000,000 |
| Other Non Operating Income Expenses | $-25,000,000 | $-9,000,000 | $-19,000,000 | $57,000,000 |
| Net Non Operating Interest Income Expense | $-426,000,000 | $-312,000,000 | $-496,000,000 | $-454,000,000 |
| Interest Expense Non Operating | $1,419,000,000 | $1,390,000,000 | $1,375,000,000 | $726,000,000 |
| Operating Expense | $10,129,000,000 | $9,985,000,000 | $9,782,000,000 | $10,464,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $6,704,000,000 | $6,335,000,000 | $5,995,000,000 | $6,950,000,000 |
| Net Interest Income | $-426,000,000 | $-312,000,000 | $-496,000,000 | $-454,000,000 |
| Interest Income | $993,000,000 | $1,078,000,000 | $879,000,000 | $272,000,000 |
| Normalized Income | $7,026,825,000 | $6,659,706,000 | $6,477,227,691 | $7,200,250,000 |
| Net Income From Continuing And Discontinued Operation | $6,704,000,000 | $6,335,000,000 | $5,995,000,000 | $6,950,000,000 |
| Total Operating Income As Reported | $7,746,000,000 | $7,337,000,000 | $6,859,000,000 | $8,393,000,000 |
| Net Income Common Stockholders | $6,704,000,000 | $6,335,000,000 | $5,995,000,000 | $6,950,000,000 |
| Net Income | $6,704,000,000 | $6,335,000,000 | $5,995,000,000 | $6,950,000,000 |
| Net Income Including Noncontrolling Interests | $6,721,000,000 | $6,338,000,000 | $5,955,000,000 | $6,960,000,000 |
| Net Income Continuous Operations | $6,721,000,000 | $6,338,000,000 | $5,955,000,000 | $6,960,000,000 |
| Earnings From Equity Interest Net Of Tax | $-41,000,000 | $-42,000,000 | $-59,000,000 | $-172,000,000 |
| Pretax Income | $7,308,000,000 | $7,037,000,000 | $6,298,000,000 | $7,835,000,000 |
| Special Income Charges | $-362,000,000 | $-379,000,000 | $-459,000,000 | $-114,000,000 |
| Interest Income Non Operating | $993,000,000 | $1,078,000,000 | $879,000,000 | $272,000,000 |
| Operating Income | $8,110,000,000 | $7,717,000,000 | $7,318,000,000 | $8,507,000,000 |
| Gross Profit | $18,239,000,000 | $17,702,000,000 | $17,100,000,000 | $18,971,000,000 |
| Per Share | ||||
| Diluted EPS | $17.74 | $16.53 | $15.45 | $17.63 |
| Basic EPS | $17.77 | $16.58 | $15.52 | $17.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $-26,175,000 | $-33,294,000 | $-22,772,309 | $-24,750,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $11,856,000,000 | $11,893,000,000 | $11,584,000,000 | $12,217,000,000 |
| Total Unusual Items | $-349,000,000 | $-358,000,000 | $-505,000,000 | $-275,000,000 |
| Total Unusual Items Excluding Goodwill | $-349,000,000 | $-358,000,000 | $-505,000,000 | $-275,000,000 |
| Reconciled Depreciation | $2,780,000,000 | $3,108,000,000 | $3,406,000,000 | $3,381,000,000 |
| EBITDA (Bullshit earnings) | $11,507,000,000 | $11,535,000,000 | $11,079,000,000 | $11,942,000,000 |
| EBIT | $8,727,000,000 | $8,427,000,000 | $7,673,000,000 | $8,561,000,000 |
| Diluted Average Shares | $378,000,000 | $383,000,000 | $388,000,000 | $394,000,000 |
| Basic Average Shares | $377,000,000 | $382,000,000 | $386,000,000 | $392,000,000 |
| Diluted NI Availto Com Stockholders | $6,704,000,000 | $6,335,000,000 | $5,995,000,000 | $6,950,000,000 |
| Minority Interests | $-17,000,000 | $-3,000,000 | $40,000,000 | $-10,000,000 |
| Tax Provision | $547,000,000 | $657,000,000 | $284,000,000 | $703,000,000 |
| Restructuring And Mergern Acquisition | $362,000,000 | $379,000,000 | $459,000,000 | $114,000,000 |
| Gain On Sale Of Security | $13,000,000 | $21,000,000 | $-46,000,000 | $-161,000,000 |
| Research And Development | $1,397,000,000 | $1,390,000,000 | $1,337,000,000 | $1,471,000,000 |
| Selling General And Administration | $8,732,000,000 | $8,595,000,000 | $8,445,000,000 | $8,993,000,000 |
Fetched: 2026-06-04
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-11,793,000,000 | $-11,801,000,000 | $-13,955,000,000 | $-14,660,000,000 |
| Total Assets | $110,343,000,000 | $97,321,000,000 | $98,726,000,000 | $97,154,000,000 |
| Total Non Current Assets | $81,636,000,000 | $75,184,000,000 | $74,137,000,000 | $71,925,000,000 |
| Other Non Current Assets | $5,871,000,000 | $4,492,000,000 | $3,999,000,000 | $4,007,000,000 |
| Goodwill And Other Intangible Assets | $65,200,000,000 | $61,386,000,000 | $60,690,000,000 | $58,638,000,000 |
| Other Intangible Assets | $15,838,000,000 | $15,533,000,000 | $16,670,000,000 | $17,442,000,000 |
| Current Assets | $28,707,000,000 | $22,137,000,000 | $24,589,000,000 | $25,229,000,000 |
| Other Current Assets | $2,611,000,000 | $1,963,000,000 | $1,757,000,000 | $1,644,000,000 |
| Inventory | $5,425,000,000 | $4,978,000,000 | $5,088,000,000 | $5,634,000,000 |
| Receivables | $10,566,000,000 | $9,626,000,000 | $9,664,000,000 | $9,427,000,000 |
| Other Receivables | $1,666,000,000 | $1,435,000,000 | $1,443,000,000 | $1,312,000,000 |
| Accounts Receivable | $8,900,000,000 | $8,191,000,000 | $8,221,000,000 | $8,115,000,000 |
| Allowance For Doubtful Accounts Receivable | $-147,000,000 | $-173,000,000 | $-193,000,000 | $-189,000,000 |
| Gross Accounts Receivable | $9,047,000,000 | $8,364,000,000 | $8,414,000,000 | $8,304,000,000 |
| Cash Cash Equivalents And Short Term Investments | $10,105,000,000 | $5,570,000,000 | $8,080,000,000 | $8,524,000,000 |
| Cash And Cash Equivalents | $9,852,000,000 | $4,009,000,000 | $8,077,000,000 | $8,524,000,000 |
| Restricted Cash | - | - | - | $12,000,000 |
| Debt | ||||
| Net Debt | $29,533,000,000 | $27,266,000,000 | $26,840,000,000 | $25,964,000,000 |
| Total Debt | $39,385,000,000 | $31,275,000,000 | $34,917,000,000 | $34,488,000,000 |
| Long Term Debt And Capital Lease Obligation | $35,852,000,000 | $29,061,000,000 | $31,308,000,000 | $28,909,000,000 |
| Long Term Debt | $35,852,000,000 | $29,061,000,000 | $31,308,000,000 | $28,909,000,000 |
| Current Debt And Capital Lease Obligation | $3,533,000,000 | $2,214,000,000 | $3,609,000,000 | $5,579,000,000 |
| Current Debt | $3,533,000,000 | $2,214,000,000 | $3,609,000,000 | $5,579,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $56,807,000,000 | $47,649,000,000 | $51,884,000,000 | $53,006,000,000 |
| Total Non Current Liabilities Net Minority Interest | $41,618,000,000 | $34,317,000,000 | $37,872,000,000 | $35,996,000,000 |
| Other Non Current Liabilities | $4,273,000,000 | $3,988,000,000 | $4,642,000,000 | $4,238,000,000 |
| Non Current Deferred Liabilities | $1,493,000,000 | $1,268,000,000 | $1,922,000,000 | $2,849,000,000 |
| Non Current Deferred Taxes Liabilities | $1,493,000,000 | $1,268,000,000 | $1,922,000,000 | $2,849,000,000 |
| Current Liabilities | $15,189,000,000 | $13,332,000,000 | $14,012,000,000 | $17,010,000,000 |
| Current Deferred Liabilities | $2,710,000,000 | $2,852,000,000 | $2,689,000,000 | $2,601,000,000 |
| Payables And Accrued Expenses | $8,946,000,000 | $8,266,000,000 | $7,714,000,000 | $8,830,000,000 |
| Payables | $3,622,000,000 | $3,079,000,000 | $2,872,000,000 | $3,381,000,000 |
| Accounts Payable | $3,622,000,000 | $3,079,000,000 | $2,872,000,000 | $3,381,000,000 |
| Equity | ||||
| Common Stock Equity | $53,407,000,000 | $49,585,000,000 | $46,735,000,000 | $43,978,000,000 |
| Total Equity Gross Minority Interest | $53,536,000,000 | $49,672,000,000 | $46,842,000,000 | $44,148,000,000 |
| Stockholders Equity | $53,407,000,000 | $49,585,000,000 | $46,735,000,000 | $43,978,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,448,000,000 | $-2,697,000,000 | $-3,224,000,000 | $-3,099,000,000 |
| Other Equity Adjustments | $-2,448,000,000 | $-2,697,000,000 | $-3,224,000,000 | $-3,099,000,000 |
| Retained Earnings | $59,156,000,000 | $53,102,000,000 | $47,364,000,000 | $41,910,000,000 |
| Other | ||||
| Treasury Shares Number | $68,938,831 | $63,066,906 | $55,541,290 | $50,157,275 |
| Ordinary Shares Number | $376,221,470 | $380,774,334 | $386,647,344 | $390,510,837 |
| Share Issued | $445,160,301 | $443,841,240 | $442,188,634 | $440,668,112 |
| Tangible Book Value | $-11,793,000,000 | $-11,801,000,000 | $-13,955,000,000 | $-14,660,000,000 |
| Invested Capital | $92,792,000,000 | $80,860,000,000 | $81,652,000,000 | $78,466,000,000 |
| Working Capital | $13,518,000,000 | $8,805,000,000 | $10,577,000,000 | $8,219,000,000 |
| Total Capitalization | $89,259,000,000 | $78,646,000,000 | $78,043,000,000 | $72,887,000,000 |
| Minority Interest | $129,000,000 | $87,000,000 | $107,000,000 | $170,000,000 |
| Treasury Stock | $22,309,000,000 | $19,226,000,000 | $15,133,000,000 | $12,017,000,000 |
| Additional Paid In Capital | $18,563,000,000 | $17,962,000,000 | $17,286,000,000 | $16,743,000,000 |
| Capital Stock | $445,000,000 | $444,000,000 | $442,000,000 | $441,000,000 |
| Common Stock | $445,000,000 | $444,000,000 | $442,000,000 | $441,000,000 |
| Preferred Stock | $0 | $0 | - | - |
| Current Deferred Revenue | $2,710,000,000 | $2,852,000,000 | $2,689,000,000 | $2,601,000,000 |
| Current Accrued Expenses | $5,324,000,000 | $5,187,000,000 | $4,842,000,000 | $5,449,000,000 |
| Goodwill | $49,362,000,000 | $45,853,000,000 | $44,020,000,000 | $41,196,000,000 |
| Net PPE | $10,565,000,000 | $9,306,000,000 | $9,448,000,000 | $9,280,000,000 |
| Accumulated Depreciation | $-7,815,000,000 | $-6,753,000,000 | $-6,076,000,000 | $-4,989,000,000 |
| Gross PPE | $18,380,000,000 | $16,059,000,000 | $15,524,000,000 | $14,269,000,000 |
| Construction In Progress | $2,305,000,000 | $2,034,000,000 | $2,238,000,000 | $2,695,000,000 |
| Machinery Furniture Equipment | $11,005,000,000 | $9,858,000,000 | $9,235,000,000 | $7,967,000,000 |
| Buildings And Improvements | $4,570,000,000 | $3,728,000,000 | $3,593,000,000 | $3,153,000,000 |
| Land And Improvements | $500,000,000 | $439,000,000 | $458,000,000 | $454,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,659,000,000 | $2,420,000,000 | $2,326,000,000 | $2,569,000,000 |
| Work In Process | $889,000,000 | $755,000,000 | $705,000,000 | $660,000,000 |
| Raw Materials | $1,877,000,000 | $1,803,000,000 | $2,057,000,000 | $2,405,000,000 |
| Other Short Term Investments | $253,000,000 | $1,561,000,000 | $3,000,000 | - |
Fetched: 2026-06-04
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $6,293,000,000 | $7,267,000,000 | $6,927,000,000 | $6,911,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $7,818,000,000 | $8,667,000,000 | $8,406,000,000 | $9,154,000,000 |
| Cash Flow From Continuing Operating Activities | $7,819,000,000 | $8,667,000,000 | $8,406,000,000 | $9,154,000,000 |
| Operating Gains Losses | - | - | - | $26,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,525,000,000 | $-1,400,000,000 | $-1,479,000,000 | $-2,243,000,000 |
| Investing Cash Flow | $-4,047,000,000 | $-5,841,000,000 | $-5,142,000,000 | $-2,159,000,000 |
| Cash Flow From Continuing Investing Activities | $-4,047,000,000 | $-5,841,000,000 | $-5,142,000,000 | $-2,159,000,000 |
| Net Other Investing Changes | $21,000,000 | $8,000,000 | $33,000,000 | $20,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-3,000,000,000 | $-4,000,000,000 | $-3,000,000,000 | $-3,000,000,000 |
| Financing Cash Flow | $1,801,000,000 | $-6,792,000,000 | $-3,622,000,000 | $-2,810,000,000 |
| Cash Flow From Continuing Financing Activities | $1,801,000,000 | $-6,791,000,000 | $-3,622,000,000 | $-2,810,000,000 |
| Net Other Financing Charges | $90,000,000 | $194,000,000 | $56,000,000 | $-9,000,000 |
| Cash Dividends Paid | $-636,000,000 | $-583,000,000 | $-523,000,000 | $-455,000,000 |
| Net Common Stock Issuance | $-3,000,000,000 | $-4,000,000,000 | $-3,000,000,000 | $-3,000,000,000 |
| Other | ||||
| Repayment Of Debt | $-3,507,000,000 | $-3,607,000,000 | $-7,717,000,000 | $-4,065,000,000 |
| Issuance Of Debt | $8,854,000,000 | $1,204,000,000 | $7,562,000,000 | $4,719,000,000 |
| Interest Paid Supplemental Data | $1,612,000,000 | $1,570,000,000 | $1,385,000,000 | $667,000,000 |
| Income Tax Paid Supplemental Data | $1,776,000,000 | $1,834,000,000 | $1,482,000,000 | $1,234,000,000 |
| End Cash Position | $9,879,000,000 | $4,040,000,000 | $8,097,000,000 | $8,537,000,000 |
| Beginning Cash Position | $4,040,000,000 | $8,097,000,000 | $8,537,000,000 | $4,491,000,000 |
| Effect Of Exchange Rate Changes | $267,000,000 | $-91,000,000 | $-82,000,000 | $-139,000,000 |
| Changes In Cash | $5,572,000,000 | $-3,966,000,000 | $-358,000,000 | $4,185,000,000 |
| Common Stock Payments | $-3,000,000,000 | $-4,000,000,000 | $-3,000,000,000 | $-3,000,000,000 |
| Net Issuance Payments Of Debt | $5,347,000,000 | $-2,403,000,000 | $-155,000,000 | $654,000,000 |
| Net Short Term Debt Issuance | $0 | $0 | $-315,000,000 | $-2,164,000,000 |
| Short Term Debt Payments | $-1,095,000,000 | $0 | $-1,935,000,000 | $-3,690,000,000 |
| Short Term Debt Issuance | $1,095,000,000 | $0 | $1,620,000,000 | $1,526,000,000 |
| Net Long Term Debt Issuance | $5,347,000,000 | $-2,403,000,000 | $160,000,000 | $2,818,000,000 |
| Long Term Debt Payments | $-2,412,000,000 | $-3,607,000,000 | $-5,782,000,000 | $-375,000,000 |
| Long Term Debt Issuance | $7,759,000,000 | $1,204,000,000 | $5,942,000,000 | $3,193,000,000 |
| Net Investment Purchase And Sale | $1,450,000,000 | $-1,374,000,000 | $-123,000,000 | $79,000,000 |
| Sale Of Investment | $1,833,000,000 | $2,022,000,000 | $85,000,000 | $131,000,000 |
| Purchase Of Investment | $-383,000,000 | $-3,396,000,000 | $-208,000,000 | $-52,000,000 |
| Net Business Purchase And Sale | $-4,037,000,000 | $-3,132,000,000 | $-3,660,000,000 | $-39,000,000 |
| Purchase Of Business | $-4,037,000,000 | $-3,132,000,000 | $-3,660,000,000 | $-39,000,000 |
| Net PPE Purchase And Sale | $-1,481,000,000 | $-1,343,000,000 | $-1,392,000,000 | $-2,219,000,000 |
| Sale Of PPE | $44,000,000 | $57,000,000 | $87,000,000 | $24,000,000 |
| Purchase Of PPE | $-1,525,000,000 | $-1,400,000,000 | $-1,479,000,000 | $-2,243,000,000 |
| Change In Working Capital | $-1,766,000,000 | $-334,000,000 | $-495,000,000 | $-1,008,000,000 |
| Change In Other Working Capital | $-1,687,000,000 | $-348,000,000 | $-550,000,000 | $-401,000,000 |
| Change In Payables And Accrued Expense | $421,000,000 | $212,000,000 | $-500,000,000 | $648,000,000 |
| Change In Payable | $421,000,000 | $212,000,000 | $-500,000,000 | $648,000,000 |
| Change In Account Payable | $421,000,000 | $212,000,000 | $-500,000,000 | $648,000,000 |
| Change In Inventory | $-74,000,000 | $-27,000,000 | $598,000,000 | $-825,000,000 |
| Change In Receivables | $-426,000,000 | $-171,000,000 | $-43,000,000 | $-430,000,000 |
| Changes In Account Receivables | $-426,000,000 | $-171,000,000 | $-43,000,000 | $-430,000,000 |
| Other Non Cash Items | $412,000,000 | $463,000,000 | $562,000,000 | $509,000,000 |
| Stock Based Compensation | $310,000,000 | $301,000,000 | $278,000,000 | $307,000,000 |
| Deferred Tax | $-639,000,000 | $-1,209,000,000 | $-1,300,000,000 | $-995,000,000 |
| Deferred Income Tax | $-639,000,000 | $-1,209,000,000 | $-1,300,000,000 | $-995,000,000 |
| Depreciation Amortization Depletion | $2,780,000,000 | $3,108,000,000 | $3,406,000,000 | $3,381,000,000 |
| Depreciation And Amortization | $2,780,000,000 | $3,108,000,000 | $3,406,000,000 | $3,381,000,000 |
| Amortization Cash Flow | $1,730,000,000 | $1,952,000,000 | $2,338,000,000 | $2,395,000,000 |
| Amortization Of Intangibles | $1,730,000,000 | $1,952,000,000 | $2,338,000,000 | $2,395,000,000 |
| Depreciation | $1,050,000,000 | $1,156,000,000 | $1,068,000,000 | $986,000,000 |
| Net Income From Continuing Operations | $6,721,000,000 | $6,338,000,000 | $5,955,000,000 | $6,960,000,000 |
| Proceeds From Stock Option Exercised | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-06-04